Current approach to iron chelation in children

British Journal of Haematology

Volumn 165, Issue 6, 2014, Pages 745-755

  Aydinok, Yesim ^a   Kattamis, Antonis ^b   Viprakasit, Vip ^c  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Chelation; Children; Iron; Sickle; Thalassaemia

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HEMOGLOBIN E; HEMOGLOBIN H; IRON;

AGRANULOCYTOSIS; ARTHROPATHY; BETA THALASSEMIA; BIOACCUMULATION; BLOOD TRANSFUSION; CHELATION THERAPY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTINUOUS INFUSION; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; IRON BALANCE; IRON CHELATION; IRON OVERLOAD; MAINTENANCE THERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SICKLE CELL ANEMIA; SURVIVAL RATE; THALASSEMIA; THROMBOCYTOPENIA;

CHELATION; CHILDREN; IRON; SICKLE; THALASSAEMIA;

ANEMIA; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; CHILD, PRESCHOOL; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; NEURODEGENERATIVE DISEASES; TREATMENT OUTCOME;

EID: 84901694795     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12825     Document Type: Review

References (98)

1. Anderson, L.J., Westwood, M.A., Holden, S., Davis, B., Prescott, E., Wonke, B., Porter, J.B., Walker, J.M. & Pennell, D.J. (2004) Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. British Journal of Haematology, 127, 348-355.
2. Angelucci, E., Muretto, P., Lucarelli, G., Ripalti, M., Baronciani, D., Erer, B., Galimberti, M., Giardini, C., Gaziev, D. & Polchi, P. (1997) Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood, 90, 994-998.
3. Aydinok, Y., Nisli, G., Kavakli, K., Coker, C., Kantar, M. & Cetingul, N. (1999) Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey. Acta Haematologica, 102, 17-21.
4. Aydinok, Y., Ulger, Z., Nart, D., Terzi, A., Cetiner, N., Ellis, G., Zimmermann, A. & Manz, C. (2007) A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica, 92, 1599-1606.
5. Aydinok, Y., Unal, S., Oymak, Y., Vergin, C., Turker, Z.D., Yildiz, D. & Yesilipek, A. (2012) Observational study comparing long-term safety and efficacy of deferasirox with desferrioxamine therapy in chelation-naive children with transfusional iron overload. European Journal of Haematology, 88, 431-438.
6. Aydinok, Y., Galanello, R., Viprakasit, V., Piga, A., Harmatz, P., Luca Forni, G.L., Shah, F.T., Grace, R.F., Porter, J.B., Vichinsky, E.J., Wood, J.C., Krishnan, S., Zhang, P., Abi-Saab, W., Rienhoff, H.Y.J. & Neufeld, E.J. (2013a) The safety, tolerability and efficacy of FBS0701, an iron chelator in clinical development for transfusional iron overload: data from 72 weeks of treatment. Haematologica, 98(Suppl 1), 487-488, abstract 1175.
7. Aydinok, Y., Kattamis, A., Cappellini, M.D., El-Beshlawy, A., Origa, R., El-Alfy, M.S., Kilinc, Y., Perrotta, S., Karakas, Z., Viprakasit, V., Habr, D., Wegener, A., Shen, J. & Porter, J.B. (2013b) Deferasirox-deferoxamine combination therapy reduces cardiac iron with rapid liver iron removal in patients with severe transfusional iron overload (HYPERION). Blood 122, abstract 2257.
8. Berdoukas, V., Nord, A., Carson, S., Puliyel, M., Hofstra, T., Wood, J. & Coates, T.D. (2013) Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age. American Journal of Hematology, 88, E283-E285.
9. Boddaert, N., Le Quan Sang, K.H., Rotig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., Sidi, D., Thalabard, J.C., Munnich, A. & Cabantchik, Z.I. (2007) Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood, 110, 401-408.
10. Borgna-Pignatti, C. & Cohen, A. (1997) Evaluation of a new method of administration of the iron chelating agent deferoxamine. Journal of Pediatrics, 130, 86-88.
11. Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Zhao, H., Cappellini, M.D., Del Vecchio, G.C., Romeo, M.A., Forni, G.L., Gamberini, M.R., Ghilardi, R., Piga, A. & Cnaan, A. (2004) Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica, 89, 1187-1193.
12. Brittenham, G.M., Cohen, A.R., McLaren, C.E., Martin, M.B., Griffith, P.M., Nienhuis, A.W., Young, N.S., Allen, C.J., Farrell, D.E. & Harris, J.W. (1993) Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. American Journal of Hematology, 42, 81-85.
13. Cabibbo, S., Fidone, C., Garozzo, G., Antolino, A., Manenti, G.O., Bennardello, F., Licitra, V., Calabrese, S., Costantino, F., Travali, S., Distefano, R. & Bonomo, P. (2005) Chronic red blood cell exchange to prevent clinical complications in sickle cell disease. Transfusion Apheresis Science, 32, 315-321.
14. Cappellini, M.D., Bejaoui, M., Agaoglu, L., Canatan, D., Capra, M., Cohen, A., Drelichman, G., Economou, M., Fattoum, S., Kattamis, A., Kilinc, Y., Perrotta, S., Piga, A., Porter, J.B., Griffel, L., Dong, V., Clark, J. & Aydinok, Y. (2011) Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood, 118, 884-893.
15. Ceci, A., Baiardi, P., Felisi, M., Cappellini, M.D., Carnelli, V., De Sanctis, V., Galanello, R., Maggio, A., Masera, G., Piga, A., Schettini, F., Stefano, I. & Tricta, F. (2002) The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. British Journal of Haematology, 118, 330-336.
16. Chen, F.E., Ooi, C., Ha, S.Y., Cheung, B.M., Todd, D., Liang, R., Chan, T.K. & Chan, V. (2000) Genetic and clinical features of hemoglobin H disease in Chinese patients. New England Journal of Medicine, 343, 544-550.
17. Cighetti, G., Duca, L., Bortone, L., Sala, S., Nava, I., Fiorelli, G. & Cappellini, M.D. (2002) Oxidative status and malondialdehyde in beta-thalassaemia patients. European Journal of Clinical Investigation, 32, 55-60.
18. Cohen, A.R., Martin, M.B., Silber, J.H., Kim, H.C., Ohene-Frempong, K. & Schwartz, E. (1992) A modified transfusion program for prevention of stroke in sickle cell disease. Blood, 79, 1657-1661.
19. Cohen, A.R., Galanello, R., Piga, A., De Sanctis, V. & Tricta, F. (2003) Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood, 102, 1583-1587.
20. Cohen, A.R., Glimm, E. & Porter, J.B. (2008) Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood, 111, 583-587.
21. Davies, S.C., Marcus, R.E., Hungerford, J.L., Miller, M.H., Arden, G.B. & Huehns, E.R. (1983) Ocular toxicity of high-dose intravenous desferrioxamine. Lancet, 2, 181-184.
22. Davis, B.A. & Porter, J.B. (2000) Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood, 95, 1229-1236.
23. Delea, T.E., Edelsberg, J., Sofrygin, O., Thomas, S.K., Baladi, J.F., Phatak, P.D. & Coates, T.D. (2007) Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion, 47, 1919-1929.
24. Dubourg, L., Laurain, C., Ranchin, B., Pondarre, C., Hadj-Aissa, A., Sigaudo-Roussel, D. & Cochat, P. (2012) Deferasirox-induced renal impairment in children: an increasing concern for pediatricians. Pediatric Nephrology, 27, 2115-2122.
25. El-Alfy, M.S., Sari, T.T., Lee, C.L., Tricta, F. & El-Beshlawy, A. (2010) The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. Journal of Pediatric Hematology Oncology, 32, 601-605.
26. El-Alfy, M.S., Wali, Y., Tony, S., Samir, A. & Adly, A. (2013) Comparison of two combination iron chelation regimens, deferiprone and deferasirox versus deferiprone and deferoxamine, in pediatric patients with β-thalassemia major. Blood (ASH Annual Meeting Abstracts), 122, 559.
27. El-Beshlawy, A., Manz, C., Naja, M., Eltagui, M., Tarabishi, C., Youssry, I., Sobh, H., Hamdy, M., Sharaf, I., Mostafa, A., Shaker, O., Hoffbrand, A.V. & Taher, A. (2008) Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Annals of Hematology, 87, 545-550.
28. El-Beshlawy, A., Elalfy, M.S., Chan, L.L., Lai, Y., Lin, K.H., Aydinok, Y., Galanello, R., Al-Ali, A., Martin, N. & Cappellini, M.D. (2012) Treatment of iron-overloaded pediatric patients with Deferasirox (Exjade): a 3-year follow up from the EPIC study. Thalassaemia Reports, 2, 22.
29. Farmaki, K., Tzoumari, I., Pappa, C., Chouliaras, G. & Berdoukas, V. (2010) Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. British Journal of Haematology, 148, 466-475.
30. Farmaki, K., Tzoumari, I. & Pappa, C. (2011) Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications. Blood Cells Molecules and Diseases, 47, 33-40.
31. Fisher, S.A., Brunskill, S.J., Doree, C., Gooding, S., Chowdhury, O. & Roberts, D.J. (2013) Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database Systematic Review, 8, CD004450.
32. Gabutti, V. & Piga, A. (1996) Results of long-term iron-chelating therapy. Acta Haematologica, 95, 26-36.
33. Galanello, R., Kattamis, A., Piga, A., Fischer, R., Leoni, G., Ladis, V., Voi, V., Lund, U. & Tricta, F. (2006a) A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica, 91, 1241-1243.
34. Galanello, R., Piga, A., Forni, G.L., Bertrand, Y., Foschini, M.L., Bordone, E., Leoni, G., Lavagetto, A., Zappu, A., Longo, F., Maseruka, H., Hewson, N., Sechaud, R., Belleli, R. & Alberti, D. (2006b) Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica, 91, 1343-1351.
35. Giardina, P.J. & Grady, R.W. (1995) Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Seminar in Hematology, 32, 304-312.
36. Gomber, S., Saxena, R. & Madan, N. (2004) Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatrics, 41, 21-27.
37. Ha, S.Y., Chik, K.W., Ling, S.C., Lee, A.C., Luk, C.W., Lam, C.W., Ng, I.O. & Chan, G.C. (2006) A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin, 30, 263-274.
38. Harmatz, P., Butensky, E., Quirolo, K., Williams, R., Ferrell, L., Moyer, T., Golden, D., Neumayr, L. & Vichinsky, E. (2000) Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood, 96, 76-79.
39. Henter, J.I. & Karlen, J. (2007) Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood, 109, 5157-5159.
40. Hoffbrand, A.V. & Wonke, B. (1989) Results of long-term subcutaneous desferrioxamine therapy. Baillieres' Clinical Haematology, 2, 345-362.
41. Inati, A., Sbeiti, N., Khoriaty, E., Cappellini, M.D., Koussa, S., Abi Nasr, T., Musallam, K.M. & Taher, A. (2011) 1-Year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassaemia major following curative stem cell transplantation. Blood (ASH Annual Meeting Abstracts), 118, 904a.
42. ®, ICL670) demonstrates iron chelated efficacy related to transfusional iron intake in paediatric patients. Blood (ASH Annual Meeting Abstracts), 106, 2692.
43. Koren, A., Fink, D., Admoni, O., Tennenbaum-Rakover, Y. & Levin, C. (2010) Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients. European Journal of Haematology, 84, 72-78.
44. Kwiatkowski, J.L. (2011) Management of transfusional iron overload -differential properties and efficacy of iron chelating agents. Journal of Blood Medicine, 2, 135-149.
45. Kwiatkowski, J.L., Kim, H.Y., Thompson, A.A., Quinn, C.T., Mueller, B.U., Odame, I., Giardina, P.J., Vichinsky, E.P., Boudreaux, J.M., Cohen, A.R., Porter, J.B., Coates, T., Olivieri, N.F. & Neufeld, E.J. (2012) Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood, 119, 2746-2753.
46. Lal, A., Goldrich, M.L., Haines, D.A., Azimi, M., Singer, S.T. & Vichinsky, E.P. (2011) Heterogeneity of hemoglobin H disease in childhood. New England Journal of Medicine, 364, 710-718.
47. Lal, A., Porter, J., Sweeters, N., Ng, V., Evans, P., Neumayr, L., Kurio, G., Harmatz, P. & Vichinsky, E. (2013) Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Molecules and Diseases, 50, 99-104.
48. Lee, J.W., Yoon, S.S., Shen, Z.X., Ganser, A., Hsu, H.C., Habr, D., Domokos, G., Roubert, B. & Porter, J.B. (2010) Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood, 116, 2448-2454.
49. Lee, J.W., Yoon, S.S., Shen, Z.X., Ganser, A., Hsu, H.C., El-Ali, A., Habr, D., Martin, N. & Porter, J.B. (2013) Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study. Haematologica, 98, 1045-1048.
50. Li, C.K., Lai, D.H., Shing, M.M.K., Chik, K.W., Lee, V. & Yuen, P.M.P. (2000) Early iron reduction programme for thalassaemia patients after bone marrow transplantation. Bone Marrow Transplantation, 25, 653-656.
51. Lucania, G., Vitrano, A., Filosa, A. & Maggio, A. (2011) Chelation treatment in sickle-cell-anaemia: much ado about nothing? British Journal of Haematology, 154, 545-555.
52. Lucas, G.N., Perera, B.J., Fonseka, E.A., De Silva, D.D., Fernandopulle, M., Karunatilaka, D.H. & Weerasinghe, I. (2002) Experience with the oral iron chelator deferiprone in transfusion-dependent children. Ceylon Medical Journal, 47, 119-121.
53. Musallam, K.M., Cappellini, M.D., Wood, J.C., Motta, I., Graziadei, G., Tamim, H. & Taher, A.T. (2011) Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica, 96, 1605-1612.
54. Musallam, K.M., Angastiniotis, M., Eleftheriou, A. & Porter, J.B. (2013) Cross-talk between available guidelines for the management of patients with beta-thalassemia major. Acta Haematologica, 130, 64-73.
55. Naithani, R., Chandra, J. & Sharma, S. (2005) Safety of oral iron chelator deferiprone in young thalassaemics. European Journal of Haematology, 74, 217-220.
56. Neufeld, E.J., Galanello, R., Viprakasit, V., Aydinok, Y., Piga, A., Harmatz, P., Forni, G.L., Shah, F.T., Grace, R.F., Porter, J.B., Wood, J.C., Peppe, J., Jones, A. & Rienhoff, H.Y. Jr (2012) A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood, 119, 3263-3268.
57. Noetzli, L.J., Carson, S.M., Nord, A.S., Coates, T.D. & Wood, J.C. (2008) Longitudinal analysis of heart and liver iron in thalassemia major. Blood, 112, 2973-2978.
58. Noetzli, L.J., Panigrahy, A., Mittelman, S.D., Hyderi, A., Dongelyan, A., Coates, T.D. & Wood, J.C. (2012) Pituitary iron and volume predict hypogonadism in transfusional iron overload. American Journal of Hematology, 87, 167-171.
59. Olivieri, N.F. & Brittenham, G.M. (2013) Management of the thalassemias. Cold Spring Harbor Perspectives in Medicine, 3, pii: a011767, doi:10.1101/cshperspect.a011767.
60. Peng, C.T., Chow, K.C., Chen, J.H., Chiang, Y.P., Lin, T.Y. & Tsai, C.H. (2003) Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. European Journal of Haematology, 70, 392-397.
61. Pennell, D.J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Aessopos, A., Gotsis, E.D., Tanner, M.A., Smith, G.C., Westwood, M.A., Wonke, B. & Galanello, R. (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 107, 3738-3744.
62. Pennell, D.J., Porter, J.B., Cappellini, M.D., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, C.K., Viprakasit, V., Elalfy, M.S., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B. & Taher, A. (2012) Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with beta-thalassemia major. Haematologica, 97, 842-848.
63. Piga, A., Luzzatto, L., Capalbo, P., Gambotto, S., Tricta, F. & Gabutti, V. (1988) High-dose desferrioxamine as a cause of growth failure in thalassemic patients. European Journal of Haematology, 40, 380-381.
64. Piga, A., Longo, F., Duca, L., Roggero, S., Vinciguerra, T., Calabrese, R., Hershko, C. & Cappellini, M.D. (2009) High nontransferrin bound iron levels and heart disease in thalassemia major. American Journal of Hematology, 84, 29-33.
65. Pippard, M.J. (1989) Desferrioxamine-induced iron excretion in humans. Baillieres' Clinical Haematology, 2, 323-343.
66. Porter, J.B. (2001) Practical management of iron overload. British Journal of Haematology, 115, 239-252.
67. Porter, J.B. (2009) Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease. Hemoglobin, 33, S37-S45.
68. Porter, J. & Garbowski, M. (2013) Consequences and management of iron overload in sickle cell disease. Hematology/the Education Program of the American Society of Hematology, 2013, 447-456.
69. Porter, J.B., Jaswon, M.S., Huehns, E.R., East, C.A. & Hazell, J.W. (1989) Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. British Journal of Haematology, 73, 403-409.
70. Porter, J.B., Abeysinghe, R.D., Marshall, L., Hider, R.C. & Singh, S. (1996) Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood, 88, 705-713.
71. Porter, J.B., Lin, K.H., Beris, P., Forni, G.L., Taher, A., Habr, D., Domokos, G., Roubert, B. & Thein, S.L. (2011) Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. European Journal of Haematology, 87, 338-348.
72. Porter, J.B., Elalfy, M.S., Taher, A.T., Aydinok, Y., Chan, L.L., Lee, S.H., Sutcharitchan, P., Habr, D., Martin, N. & El-Beshlawy, A. (2013) Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy. Annals of Hematology, 92, 211-219.
73. Roggero, S., Quarello, P., Vinciguerra, T., Longo, F., Piga, A. & Ramenghi, U. (2009) Severe iron overload in Blackfan-Diamond anemia: a case-control study. American Journal of Hematology, 84, 729-732.
74. Taher, A., Sheikh-Taha, M., Sharara, A., Inati, A., Koussa, S., Ellis, G., Dhillon, A.P. & Hoffbrand, A.V. (2005) Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. Acta Haematologica, 114, 146-149.
75. Taher, A., Cappellini, M.D., Vichinsky, E., Galanello, R., Piga, A., Lawniczek, T., Clark, J., Habr, D. & Porter, J.B. (2009) Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. British Journal of Haematology, 147, 752-759.
76. Taher, A., Elalfy, M.S., Al Zir, K., Daar, S., Al Jefri, A., Habr, D., Kriemler-Krahn, U., El-Ali, A., Roubert, B. & El-Beshlawy, A. (2011) Importance of optimal dosing >/= 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with beta-thalassaemia. European Journal of Haematology, 87, 355-365.
77. Taher, A.T., Viprakasit, V., Musallam, K.M. & Cappellini, M.D. (2013a) Treating iron overload in patients with non-transfusion-dependent thalassemia. American Journal of Hematology, 88, 409-415.
78. Taher, A., Vinchinsky, E., Musallam, K.M., Cappellini, M.D. & Viprakasit, V. (eds.) (2013b) Guidelines for the Management of Non-Transfusion Dependent Thalassaemia (NTDT). Thalassaemia International Federation, Nicosia, Cyprus.
79. Taher, A.T., Porter, J.B., Viprakasit, V., Kattamis, A., Chuncharunee, S., Sutcharitchan, P., Siritanaratkul, N., Galanello, R., Karakas, Z., Lawniczek, T., Habr, D., Ros, J., Zhang, Y. & Cappellini, M.D. (2013c) Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. American Journal Hematology, 88, 503-506.
80. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Roughton, M., Assomull, R., Nair, S.V., Walker, J.M. & Pennell, D.J. (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation, 115, 1876-1884.
81. Tavazzi, D., Duca, L., Graziadei, G., Comino, A., Fiorelli, G. & Cappellini, M.D. (2001) Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes. British Journal of Haematology, 112, 48-50.
82. Telfer, P.T., Prestcott, E., Holden, S., Walker, M., Hoffbrand, A.V. & Wonke, B. (2000) Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. British Journal of Haematology, 110, 971-977.
83. Velasco-Sanchez, D., Aracil, A., Montero, R., Mas, A., Jimenez, L., O'Callaghan, M., Tondo, M., Capdevila, A., Blanch, J., Artuch, R. & Pineda, M. (2011) Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum, 10, 1-8.
84. Vichinsky, E., Onyekwere, O., Porter, J., Swerdlow, P., Eckman, J., Lane, P., Files, B., Hassell, K., Kelly, P., Wilson, F., Bernaudin, F., Forni, G.L., Okpala, I., Ressayre-Djaffer, C., Alberti, D., Holland, J., Marks, P., Fung, E., Fischer, R., Mueller, B.U. & Coates, T. (2007) A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology, 136, 501-508.
85. Vichinsky, E., Bernaudin, F., Forni, G.L., Gardner, R., Hassell, K., Heeney, M.M., Inusa, B., Kutlar, A., Lane, P., Mathias, L., Porter, J., Tebbi, C., Wilson, F., Griffel, L., Deng, W., Giannone, V. & Coates, T. (2011) Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. British Journal of Haematology, 154, 387-397.
86. Viprakasit, V. (2013) Alpha-thalassaemia: from clinical and molecular diagnosis to bedside management. Hematology Education: The Education Programme for The Annual Congress of The European Hematology Association, 1, 329-338.
87. Viprakasit, V., Tanphaichitr, V.S., Mahasandana, C., Assteerawatt, A., Suwantol, L., Veerakul, G., Kankirawatana, S., Pung-Amritt, P. & Suvatte, V. (2001) Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens. Journal Medical Association of Thailand, 84, 929-941.
88. Viprakasit, V., Tanphaichitr, V.S., Chinchang, W., Sangkla, P., Weiss, M.J. & Higgs, D.R. (2004) Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with beta thalassemia. Blood, 103, 3296-3299.
89. Viprakasit, V., Nakavachara, P., Sangpraypan, T., Weerakulwattana, L., Kiattisakthavee, P., Chaichanwatanakul, K. & Vatana, N. (2007) Osteopenia is commonly present in prepubertal children with severe Hb E/β-thal despite adequate transfusion and iron chelation therapy. Blood, 110, abstract 3830.
90. Viprakasit, V., Nuchprayoon, I., Chuansumrit, A., Torcharus, K., Pongtanakul, B., Laothamatas, J., Srichairatanakool, S., Pooliam, J., Supajitkasem, S., Suriyaphol, P., Tanphaichitr, V.S. & Tuchinda, S. (2013) Deferiprone (GPO-L-ONE (R)) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. American Journal of Hematology, 88, 251-260.
91. Vlachos, A. & Muir, E. (2010) How I treat Diamond-Blackfan anemia. Blood, 116, 3715-3723.
92. Voskaridou, E., Ladis, V., Kattamis, A., Hassapopoulou, E., Economou, M., Kourakli, A., Maragkos, K., Kontogianni, K., Lafioniatis, S., Vrettou, E., Koutsouka, F., Papadakis, A., Mihos, A., Eftihiadis, E., Farmaki, K., Papageorgiou, O., Tapaki, G., Maili, P., Theohari, M., Drosou, M., Kartasis, Z., Aggelaki, M., Basileiadi, A., Adamopoulos, I., Lafiatis, I., Galanopoulos, A., Xanthopoulidis, G., Dimitriadou, E., Mprimi, A., Stamatopoulou, M., Haile, E.D., Tsironi, M., Anastasiadis, A., Kalmanti, M., Papadopoulou, M., Panori, E., Dimoxenou, P., Tsirka, A., Georgakopoulos, D., Drandrakis, P., Dionisopoulou, D., Ntalamaga, A., Davros, I. & Karagiorga, M. (2012) A national registry of haemoglobinopathies in Greece: deducted demographics, trends in mortality and affected births. Annals of Hematology, 91, 1451-1458.
93. Walter, P.B., Fung, E.B., Killilea, D.W., Jiang, Q., Hudes, M., Madden, J., Porter, J., Evans, P., Vichinsky, E. & Harmatz, P. (2006) Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. British Journal of Haematology, 135, 254-263.
94. Wood, J.C., Tyszka, J.M., Carson, S., Nelson, M.D. & Coates, T.D. (2004) Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood, 103, 1934-1936.
95. Wood, J.C., Origa, R., Agus, A., Matta, G., Coates, T.D. & Galanello, R. (2008) Onset of cardiac iron loading in pediatric patients with thalassemia major. Haematologica, 93, 917-920.
96. Wood, J.C., Kang, B.P., Thompson, A., Giardina, P., Harmatz, P., Glynos, T., Paley, C. & Coates, T.D. (2010) The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood, 116, 537-543.
97. Yarali, N., Fisgin, T., Duru, F., Kara, A., Ecin, N., Fitoz, S. & Erden, I. (2006) Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion. Journal of Pediatric Hematology Oncology, 28, 11-16.
98. Zorzi, G., Zibordi, F., Chiapparini, L., Bertini, E., Russo, L., Piga, A., Longo, F., Garavaglia, B., Aquino, D., Savoiardo, M., Solari, A. & Nardocci, N. (2011) Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Movement Disorder, 26, 1756-1759.